Welcome to our dedicated page for OKYO Pharma SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
Patil Rajkumar V. reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that Chief Scientific Officer Rajkumar V. Patil received a grant of 3,363 shares of common stock on July 27, 2026, at $1.49 per share. Following this award, he directly owns 20,030 shares of OKYO Pharma common stock.
OKYO Pharma Ltd reports that Chief Scientific Officer Rajkumar V. Patil holds common stock and multiple stock option awards as of March 18, 2026. Direct common stock holdings total 16,667 shares. The options cover various grants over common stock with exercise prices between $1.46 and $2.75, including tranches such as 59,615 and 23,126 underlying shares, with expirations from 2033 through 2035.
OKYO Pharma Limited reported that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on Nasdaq at $1.49 per share, increasing his total holding to 20,030 ordinary shares.
The company is a clinical-stage biopharmaceutical business focused on neuropathic corneal pain and anterior segment eye diseases and plans a global Phase 3 pivotal trial of urcosimod in the second half of the year, enrolling approximately 111 patients. This disclosure is incorporated by reference into its Form F-3 registration statement (Reg. No. 333-293145).
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, reports that senior management will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026.
The chief executive officer, chief financial officer and chief medical officer will be available for one-on-one meetings. The company also states that it plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain. This report is incorporated by reference into OKYO Pharma’s Registration Statement on Form F-3 (No. 333-293145).
OKYO Pharma Ltd reported that CEO Robert John Dempsey received a grant or award of 15,000 shares of common stock on July 22, 2026 at a reported value of $1.539 per share. Following this non-derivative acquisition, he directly holds 15,000 common shares. The transaction was not made under a Rule 10b5-1 trading plan.
CERRONE GABRIELE M reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, received a grant/award of 22,500 common shares on 2026-07-21 at 1.45 per share. Following this award, his indirect holdings total 10,873,916 common shares.
JACOB GARY S reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that Chief Development Officer Gary S Jacob received a grant of 3,500 shares of common stock on July 21, 2026, at $1.40 per share. After this non-derivative grant, he directly owns 112,420 common shares. The award was not made under a Rule 10b5-1 trading plan.
OKYO Pharma Ltd director John P Brancaccio reported a grant of 5000 shares of common stock on 2026-07-21. The award, coded as a “grant, award, or other acquisition,” was priced at $1.4770 per share and increased his direct holdings to 35201 shares. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
OKYO Pharma Limited reports that Non-Executive Director John Brancaccio purchased 5,000 of its ordinary shares on Nasdaq at $1.48 per share, increasing his holding to 35,201 shares. The information is furnished and incorporated by reference into an existing Form F-3 registration statement.
The company describes itself as a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. It plans a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, enrolling approximately 111 patients on a single-dose regimen.
OKYO Pharma Limited reported that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share on July 23, 2026.
OKYO is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases and plans a global Phase 3 pivotal trial of urcosimod in the second half of this year, enrolling approximately 111 patients on a single-dose regimen.